
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics PLC is positioned positively due to the anticipated improvement in the overall response rate (ORR) for its combination therapy Zele with Keytruda, potentially rising to 55%, benefiting from favorable key opinion leader (KOL) feedback on its superiority over existing treatments like Padcev. Additionally, the company's product candidates, particularly BT5528, are expected to offer enhanced safety and tolerability compared to earlier-generation antibody-drug conjugates, which may lead to increased clinical efficacy and adoption. Furthermore, the rising investor interest in the company's innovative Bicycle design underscores the potential for expanded tumor targeting and improved safety profiles, particularly within the burgeoning radiopharmaceutical sector.
Bears say
Bicycle Therapeutics has faced significant stock pressure, with shares declining 45% year-to-date, primarily attributed to perceived weaknesses in its clinical data and increased competition in its oncology indications. Furthermore, uncertainties surrounding its product candidate Zelenectide's efficacy compared to market competitors like Padcev create potential risks, including a projected 25% downside if safety concerns arise. In addition, the company may face challenges from third-party IP issues and a shift in the development landscape towards next-generation macrocyclic peptides, which could negatively impact its competitive positioning and overall platform valuation.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares